ASBP (Aspire Biopharma Holdings, Inc. Common Stock) Stock Analysis - News
Aspire Biopharma Holdings, Inc. Common Stock (ASBP) is a publicly traded Healthcare sector company. As of May 21, 2026, ASBP trades at $5.98 with a market cap of $8.09M and a P/E ratio of 0.00. ASBP moved +2.06% today. Year to date, ASBP is -95.82%; over the trailing twelve months it is -97.91%. Its 52-week range spans $3.31 to $11,832.00. Rallies surfaces ASBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ASBP news today?
Aspire Biopharma Approves One-for-Thirty Reverse Split to Meet Nasdaq Bid Rule: Aspire Biopharma will implement a one-for-thirty reverse split on May 11, 2026, reducing outstanding shares from about 36.33 million to 1.21 million and adopting new CUSIP 738920305. The move is aimed at meeting Nasdaq's minimum bid price requirement while adjusting all options, warrants and incentive awards.
Fell Donald G. bought 10.50K (~$4.09K) on Jun 5, 2025.
Fell Donald G. sold 10.50K (~$4.09K) on Jun 5, 2025.
Fell Donald G. bought 9.50K (~$3.71K) on Jun 4, 2025.
ASBP Analyst Consensus
ASBP analyst coverage data. Average price target: $0.00.
Common questions about ASBP
What changed in ASBP news today?
Aspire Biopharma Approves One-for-Thirty Reverse Split to Meet Nasdaq Bid Rule: Aspire Biopharma will implement a one-for-thirty reverse split on May 11, 2026, reducing outstanding shares from about 36.33 million to 1.21 million and adopting new CUSIP 738920305. The move is aimed at meeting Nasdaq's minimum bid price requirement while adjusting all options, warrants and incentive awards.
Does Rallies summarize ASBP news?
Yes. Rallies summarizes ASBP news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ASBP research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ASBP. It does not provide personalized investment advice.
